Table 1 Demographic and perioperative characteristics
N (%) | Overall population | Symptomatic AL (SAL) | Asymptomatic AL (AAL) | Without AL (WAL) | P |
|---|---|---|---|---|---|
200 (100) | 29 (14.5) | 10 (5.0) | 161 (80.5) | ||
Age (years). median ± IQR | 67 (59–73) | 67 (58–73) | 70 (67–78) | 66 (59–73) | |
≥ 60 years. n (%) | 145 (72.5) | 21 (72.4) | 8 (80.0) | 116 (72.0) | 0.526 |
< 60 years. n (%) | 55 (27.5) | 8 (27.6) | 2 (20.0) | 45 (28.0) | |
Sex ratio (Female/Male) | 65/135 | 7/22 | 3/7 | 55/106 | 0.561 |
BMI (kg/m2). median ± IQR | 24 (23–28) | 24 (23–26) | 30 (25–34) | 24 (23–27) | 0.017 |
ASA Score. n (%) | |||||
1 | 107 (53.5) | 16 (55.2) | 2 (20.0) | 89 (55.3) | |
2 | 79 (39.5) | 11 (37.9) | 7 (70.0) | 61 (37.9) | 0.306 |
3 | 14 (7.0) | 2 (6.9) | 1 (10.0) | 11 (6.8) | |
Arteriopathy. n (%) | 16 (8.0) | 2 (6.9) | 2 (20.0) | 12 (7.5) | 0.355 |
Diabetes. n (%) | 23 (11.4) | 4 (13.8) | 1 (10.0) | 18 (11.2) | 0.862 |
Tumor diagnosis. n (%) | |||||
Screening test | 41 (20,5) | 8 (27.6) | 1 (10.0) | 32 (19.9) | 0.447 |
Symptoms | 159 (79.5) | 21 (72.4) | 9 (90.0) | 129 (80.1) | |
Rectal adenocarcinoma location, n (%) | |||||
Upper (10–15 cm) | 53 (26.5) | 5 (17.2) | 1 (10.0) | 47 (29.2) | |
Mid (5–10 cm) | 105 (52.5) | 18 (62.1) | 8 (80.0) | 79 (49.1) | 0.308 |
Low (2–5 cm) | 42 (21.0) | 6 (20.7) | 1 (10.0) | 35 (21.7) | |
Neoadjuvant radiation therapy, n (%) | |||||
Long-course radiotherapy (with chemotherapy) | 138 (69,0) | 19 (65.5) | 8 (80.0) | 111 (68.9) | |
Short-course radiotherapy (without chemotherapy) | 12 (6.0) | 2 (6.9) | 0 | 10 (6.2) | 0.855 |
None | 50 (25.0) | 8 (27.6) | 2 (20.0) | 40 (24.8) | |